Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-fraumeni syndrome

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 8, 2012, Pages 939-942

  Henry, Eve ^a   Villalobos, Victor ^a   Million, Lynn ^b   Jensen, Kristin C ^a,c   West, Robert ^a   Ganjoo, Kristen ^a   Lebensohn, Alexandra ^b   Ford, James M ^a,b   Telli, Melinda L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BLINDNESS; BLURRED VISION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LUNG NODULE; LYMPH NODE DISSECTION; MOLECULAR DIAGNOSIS; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PHENOTYPE; PHOTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION FIELD; SKINFOLD; THORAX WALL TUMOR; TUMOR VOLUME;

EID: 84865329221     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0097     Document Type: Article

References (22)

1. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643-6650.
2. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250-1256.
3. Lustbader ED, WilliamsWR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet 1992;51:344-356.
4. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-611.
5. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumours in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238-242.
6. Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005;103:2391-2396.
7. Kony SJ, de Vathaire F, Chrompret A, et al. Radiation and genetic factors in the risk of second malignant neoplasm's after a first cancer in childhood. Lancet 1997;350:91-95.
8. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-5362.
9. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer post operative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010;5:104-109.
10. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chrompret criteria for Li-Fraumeni syndrome. J Clin Oncol 2009;27:108-109.
11. Greenburg CC, Lipsitz SR, Hughs ME, et al. Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg 2011;254:339-345.
12. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238-242.
13. Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol 2011;21:43-50.
14. Rubino C, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;895:840-846.
15. Kleinerman RA. Radiation-sensitivie gentetically susceptible pediatric sub-populations. Pediatr Radiol 2009;39(Suppl 1):S27-31.
16. Schneider K, Garber J. Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR, et al, eds. Gene Reviews. Seattle, WA: University of Washington; 1999.
17. Daly MB, Axilbund JE, Buys S, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1, 2012. Available at NCCN.org. Accessed June 18, 2012.
18. Gonzalez KD, Buzin CH, Noltner KA, et al, High frequency of de novo mutations in Li-Fraumeni. J Med Genet 2009;46:689-693.
19. Malkin D, Smyth K, Shuman C, et al. Establishment of a dedicated cancer genetics program in a tertiary pediatric center [abstract]. Am J Hum Genet 1999;65:Abstract 386.
20. Masciari S, Dillon D, Dick MG, et al. Breast cancer phenotype in women with TP53 germ-line mutations: an LFS consortium effort [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 1519.
21. Wilson JR, Bateman AC, Hansons H, et al. A novel Her2 positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771-774.
22. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset Her2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908-913.